Moon, Tae Seok et al. "Use of modular, synthetic scaffolds for improved production of glucaric acid in engineered E. coli." Metabolic Engineering 12.3 (2010): 298-305. The field of metabolic engineering has the potential to produce a wide variety of 2 chemicals in both an inexpensive and ecologically-friendly manner. Heterologous 3 expression of novel combinations of enzymes promises to provide new or improved 4 synthetic routes towards a substantially increased diversity of small molecules. Recently, 5
(IPTG = 0.025 to 0.2 mM; aTc = 27 to 215 nM). An inoculum was prepared in LB 1 medium, and 1 % (v/v) was used to inoculate 250-mL baffled flasks containing 50 mL of 2 medium. The cultures were incubated at 30°C and 250 rpm for 2 days, and then D-3 glucaric acid titer was analyzed using HPLC as described previously (Moon et al., 4 2009a). 5 6
Assay for activity of MIOX, Ino1, and Udh 7
Assays for MIOX activity were performed using lysates as described previously 8 (Moon et al., 2009b) . Briefly, lysates were prepared by suspending cell pellets in sodium 9 phosphate buffer (50 mM, pH 8.0) with 1 mg/mL lysozyme and EDTA-free protease 10 inhibitor cocktail tablets (Roche Applied Science, Indianapolis, IN) and then by 11 sonication, followed by centrifugation to remove insolubles. The total protein 12 concentration of lysates was determined using the Bradford method (Bradford, 1976) . 13 The MIOX activity was measured by monitoring D-glucuronic acid produced when 14 excess (60 mM) myo-inositol was incubated with lysates. For the determination of D-15 glucuronic acid produced, the reaction mixture also contained excess NAD + and purified 16
Udh (Yoon et al., 2009) , stoichiometrically generating NADH which can be determined 17 by absorbance at 340 nm. Control reactions were established without myo-inositol to 18 account for background. Assays for Ino1 and Udh activity were also performed using 19 lysates as described previously (Moon et al., 2009a) . 20 21
Western Blots 22
Lysates samples were separated by SDS-PAGE and transferred onto a 1 nitrocellulose blotting membrane (Pall Life Sciences, Port Washington, NY) according to 2 the manufacturer's instructions (Bio-Rad, Hercules, CA). Anti-MIOX antibody was used 3 as described by the manufacturer (Santa Cruz Biotechnology, Santa Cruz, CA), and 4 immuno-detection was performed using anti-goat IgG-HRP and Western Blotting 5 Luminal Reagent (Santa Cruz Biotechnology, Santa Cruz, CA) according to the 6 manufacturer's instructions. 7 8 9
Results 10

The effect of Ino1 and MIOX co-localization on D-glucaric acid titer and MIOX 11 activity 12
Previous studies on the production of D-glucaric acid showed that the MIOX-13 catalyzed step is limiting and that MIOX activity is strongly influenced by the 14 concentration of myo-inositol, its substrate (Moon et al., 2009a) . We previously 15 designed a simple scaffold that co-recruits Ino1 and MIOX in a 1:1 ratio and showed that 16 D-glucaric acid titers were improved by 200% (Dueber et al., 2009 ). To determine 17 whether this titer improvement was accompanied by activity changes in the most limiting 18 step, we measured MIOX activity in lysate samples. Activity in the scaffolded system 19 was 19.0±0.9 nmol/min/mg, more than 25% higher than the scaffold-free system activity 20 of 15.0±1.3 nmol/min/mg (p=0.013). Given this result, we inquired whether increased 21 MIOX activities could be observed by changing the scaffold architecture. 22 23 
Constructing various synthetic scaffold devices 1
The previous results suggested that MIOX activity was indeed enhanced by co-2 localization, but that system was limited by the inability to independently control scaffold 3 and enzyme expression levels. Additionally, only one scaffold architecture of a 1:1 4 recruiting domain ratio was tested, which may not be optimal for maximizing the local 5 myo-inositol concentration. Here, we took advantage of the modular design of the 6 synthetic scaffolds to vary the number of interaction domains of Ino1 and MIOX for 7 control over relative enzyme stoichiometry. In particular, our hypothesis predicts 8 improved titers to be achievable for architectures with higher numbers of Ino1-recruiting 9
Src homology 3 (SH3) domains on the scaffold that would produce higher concentrations 10 of myo-inositol at the complex. The increased numbers of SH3 domains should result in 11 increased MIOX activation with a concomitant increase in D-glucaric acid production. 12
However, if increasing the number of MIOX-recruiting PSD95/DlgA/Zo-1 (PDZ) 13 domains results in substantial titer improvement, the scaffold effect is more likely due to 14 shorter transit time of substrates and higher effective concentrations of MIOX, balancing 15 the overall flux. Of course, these two mechanisms are not mutually exclusive. 16 
17
For independent expression control of the glucaric acid synthetic pathway and the 18 scaffolds, we used orthogonal IPTG-inducible (P lac ) and tetracycline-inducible (P tet ) 19 promoters, respectively, to drive expression. We used a two plasmid expression 20 platform: the enzymes for biosynthesis of glucaric acid were cloned into a p15A-based 21 medium copy plasmid, and the scaffolds were cloned into a ColE1-based high copy 22 plasmid (Table 1 ). Scaffolds were constructed by assembling three protein-protein 23 interaction domains linked together by nine-residue glycine-serine linkers predicted to be 1 flexible and unstructured. The GTPase binding domain (GBD), SH3, and PDZ domains 2 were used to target Udh, Ino1, and MIOX, respectively. As the first test, a matrix of nine 3 constructs was designed: GBD a SH3 c PDZ b where a=1 and b and c are 1, 2, or 4 (Table 1) . 4
Because Udh activity was more than 2 orders of magnitude higher than that of Ino1 and 5 MIOX (Moon et al., 2009a) , all the scaffolds were designed to contain only one GBD 6 domain (a=1). 7 8 To determine the most favorable expression levels, D-glucaric acid production by 9 GBD 1 SH3 4 PDZ 4 was tested at different aTc and IPTG concentrations (Fig. 1) . The 10 highest titers were observed with IPTG and aTc concentrations of 0.05 mM and 108 nM, 11 respectively, which led to ~5-fold titer improvement (compared to scaffold-free control). 12
It is well-known that over-expression of recombinant enzymes can have a deleterious 13 effect on cell growth in an unpredictable manner and that, ultimately, expression levels 14 that are too high actually lead to decreases in productivity (Bentley et 108, and 54 nM aTc) (Fig. 2) . The results indicate that D-glucaric acid titer primarily 5 depends on the number of Ino1-recruiting SH3 domains, not on the number of MIOX-6 recruiting PDZ domains. This observation supports the hypothesis that enhancement of 7 MIOX activation by the myo-inositol substrate is responsible for the majority of the 8 scaffolding's beneficial effect, since recruiting additional Ino1 enzymes should increase 9 the local myo-inositol concentration while leaving the number of localized MIOX 10 enzymes unchanged. The highest titers were achieved at moderate scaffold induction 11 levels, consistent with the expectation that too high of a scaffold to enzyme ratio would 12 result in a small number of recruited enzymes per scaffold molecule, resulting in small 13 titer improvement with increasing number of SH3 domains targeting Ino1. 14 
15
Given that the number of PDZ domains targeting MIOX does not affect the titer 16 considerably, we constructed additional scaffolds where the number of PDZ domains was 17 held constant at two and the number of SH3 domains was varied up to 8 (Fig. 3) . 18
Because the probability of recombination increases as the number of identical repeat 19 sequences is increased, we built this new class of scaffolds with degenerate coding 20 sequences for the SH3 domain with consideration of E. coli preferred codon usage. To 21 verify that it is the interaction activities of the domains and not the codon usage that 22 determines the scaffolding effect, two different constructs for GBD 1 SH3 2 PDZ 2 and 23 GBD 1 SH3 4 PDZ 2 were compared: one with the same SH3 sequences (JT5 and JT8, 1 respectively), and the other with the degenerate sequences (JTK4 and JTK6, 2 respectively). There were no statistically significant differences in the titers observed 3 between constructs with identical and degenerate nucleotide sequences (Table 2) . 4
Increasing the number of SH3 domains past four repeats was not accompanied by an 5 increase in titer (Fig. 3 ). In fact, there was a decrease in titers at the higher concentrations 6 of scaffold inducer (81 and 108 nM aTc). There are several potential explanations for 7 this decrease: 1. Sequestering effects, where the enzymes bind separate scaffold 8 molecules and leave many unoccupied sites, are expected to become more prevalent with 9 an increasing number of SH3 domains. 2. The recruited enzymes (e.g., Ino1 and MIOX) 10 may become oriented in less efficient ways with increasing domain number. 3. Longer 11 scaffolds with higher domain numbers may exhibit reduced stability and/or solubility. 12
Any sequestering effect could potentially be overcome by an increase in enzyme levels 13 via the concentration of the inducer IPTG. To investigate this possibility, we tested D-14 glucaric acid production by GBD 1 SH3 c PDZ 2 where c is 3, 6, and 8 at four different IPTG 15 concentrations (Fig. 4) . Higher IPTG concentrations did not lead to titer enhancement, 16 suggesting that metabolic burden effects are affecting productivity. We should also note 17 that in this system, the synthetic pathway is consuming glucose-6-phosphate, the entry 18 molecule for carbon flux into endogenous metabolism. Thus, in addition to burden 19 specifically associated with recombinant protein expression, negative effects on 20 productivity may result from variations in the flux distribution at this node that result 21 from competition between the glycolysis and pentose phosphate pathways and glucaric 22 acid production. No clear trends were evident from an examination of the cell densities 23 (represented as optical density at 600 nm) from the various scaffold architectures and 1 induction levels (Supplementary Tables S1-S3 ). However, in several cases, the highest 2 titers did correspond to the highest specific productivities. 3 4 For direct evidence that the scaffolds affect D-glucaric acid titer by improving 5 MIOX activation, we measured MIOX activity from multiple systems with various 6 scaffold architectures and compared the specific activities with the corresponding titers 7 (Fig. 5 ). Given that (1) the D-glucaric acid titer is proportional to MIOX activity and (2) 8 MIOX activity depends on the effective number of Ino1 molecules colocalized, we 9 hypothesized that titer improvement by scaffolds in our systems is strongly affected by 10 MIOX activation, most likely as the result of increased local myo-inositol concentration. 11
However, an alternative explanation is that the scaffolds inherently alter the stability 12 and/or activity of the MIOX enzyme and this effect is independent of substrate 13 concentration. To test this hypothesis, we first examined relative MIOX protein levels 14 using Western blots with anti-MIOX antibodies, with protein levels normalized to a 15 sample with non-scaffolded proteins (scaffold architecture 0:0:0) (Fig. 6) Therefore, the increase in MIOX activity is not the result of higher protein levels in this 2 system as the result of increased stability. Next, we investigated the dependence on 3 substrate. The myo-inositol in this system is produced from glucose. Thus, if the 4 scaffold effect is indeed independent of metabolite concentration, then the MIOX activity 5 should be independent of glucose presence. In all scaffold architectures examined, the 6 MIOX activity was low in the absence of glucose, and there are no significant differences 7 in activity with non-scaffolded and scaffolded MIOX (Fig. 7 - Figures S1 and S2) . These results indicate 13 that the improvement in MIOX activity is dependent on both the scaffold and substrate 14 being present, supporting our hypothesis that MIOX is activated in a substrate-dependent 15 manner, improved by co-localization of Ino1 to the scaffold. 16 
18
Discussion 19
Enzymatic activities of engineered metabolic pathways must be balanced to 20 achieve high titers, especially when these enzymes are heterologous to the production 21 host. As a result, this has been an area of intense focus where enzyme expression levels 22 are controlled or enzyme activities are improved via directed evolution (Alper et however, a great need exists for additional strategies that are orthogonal, but additive, to 4 achieve further gains in production yields if metabolic engineering is to prove viable for a 5 wider spectrum of compounds, especially bulk compounds. One such strategy may be 6 the use of synthetic scaffolds to co-target metabolic enzymes to the same complex to 7 increase the effective concentration of each pathway component. Recently, scaffolding 8 was shown to be highly effective for improving titers of the mevalonate pathway while 9 simultaneously lowering the enzyme expression levels required to achieve these titers 10 (Dueber et al., 2009). As a result, the production cells grew considerably faster than the 11 non-scaffolded pathway expressed to levels required to achieve comparable titers. In the 12 present study, the modular architecture was utilized for the glucaric acid pathway to shown to possess activity against myo-inositol-1-phosphate (Matsuhisa et al., 1995) . We 17 have over-expressed the suhB gene in an attempt to improve glucaric acid productivity; 18 however, the titers have always decreased in response to suhB (data not shown). For this 19 reason, we decided to focus on the heterologous enzymes for targeting to the scaffold. 20
The resulting improvements in MIOX activity could mean that phosphatase activity 21 remains sufficiently high and proximal to the scaffolds to produce myo-inositol. 22 Alternatively, the activation effect that we propose may also be mediated by myo-23 inositol-1-phosphate. As indicated in Fig. 7 and Supplementary Figure S2 , MIOX 1 activity still remains significantly below the most active enzyme, Udh. Understanding the 2 proper role of the phosphatase and altering its activity might provide additional 3 enhancements in MIOX activity and glucaric acid titer. 4
5
We were unable to achieve as large an improvement in glucaric acid titers as 6 previously achieved for mevalonate biosynthesis (77-fold). Multiple reasons for this 7 difference, as well as potential challenges of generalizing this scaffold strategy towards 8 other systems, were well reviewed by DeLisa and Conrado (DeLisa and Conrado, 2009). 9
Understanding the limitations of the scaffold device is indeed important for maximizing 10 its utility; therefore, we point out several significant differences between the mevalonate 11 system and the synthetic glucaric acid pathway. Firstly, the bottleneck enzymatic step in 12 the mevalonate biosynthetic pathway results in an accumulation of a toxic intermediate 13 (HMG-CoA). Thus, testing the matrix of scaffolds for improved titers was equivalent to 14 screening for improved flux of this bottleneck step and reduction of toxicity to the E. coli 15 production host. Unfortunately, these simultaneous effects cannot be easily 16 deconvoluted. For the glucaric acid production pathway, the bottleneck is MIOX activity 17 that is improved with increased substrate concentrations, but there is no indication of 18 intermediate toxicity. Consequently, the scaffolds that worked best were the ones 19 predicted to increase the effective concentration of myo-inositol at the resultant 20 complexes and not necessarily those that formed complexes with structures resulting in 21 improved, balanced fluxes of each enzymatic step. Secondly, in the glucaric acid system, 22 the increase in activity of the rate-limiting MIOX enzyme as the result of co-localization 23 with Ino1 affects both the characteristic diffusion and characteristic reaction times, 1 whereas co-recruitment of the enzymes in the mevalonate pathway should not affect the 2 underlying kinetics. Again, because of the nature of the enhancement, we cannot 3 deconvolute these two effects. Lastly, it should also be emphasized that we do not have 4 the ability to predict the structural properties of the scaffolded complexes. These are 5 likely to be complicated by the oligomerization state of the pathway enzymes. For 6 example, a tetrameric enzyme will contain four scaffold-recruiting peptide ligands. Thus, 7 the final scaffolded complex could be quite large and the optimal mevalonate 8 biosynthetic complex is likely to differ considerably from the optimal glucaric acid 9 biosynthetic complex. Given these factors, it is difficult to predict the performance of the 10 scaffolds when applied to a new pathway. However, in the absence of such factors, we 11 would expect the scaffolds to be most useful in diffusion-limited systems. Indeed, the 12 mevalonate pathway intermediates are significantly larger than those of the glucaric acid 13 pathway and should thus be expected to suffer from relativity lower diffusivity. 14 Additionally, the baseline titers achieved for glucaric acid production were significantly 15 higher, leaving much less room for improvement. 16 
17
In this study, we were able to treat metabolic enzymes as modular parts that can 18 be combined in novel combinations to produce the high-value product glucaric acid. 19 Similarly, we were able to take advantage of the functional and physical modularity of 20 the metazoan protein-protein interaction domains to build synthetic scaffolds for the 21 directed purpose of forming a synthetic complex with increased local concentrations of 22 intermediate myo-inositol. Further, we were able to change the relative product titers 23 depending on the number of enzymes producing myo-inositol expected to be recruited to 1 the complex, consistent with a titration in this local metabolite concentration. In this 2 manner, we used modularity as an engineering strategy similar to how it has facilitated 3 evolution of new signaling connections in living cells (Pawson and Nash, 2003) . We 4 observed maximum titers of ~2.5 g/L glucaric acid. This value represents a 5-fold 5 improvement over the non-scaffolded enzymes expressed from the same vectors, and an 6 approximately 50% improvement of our previously highest reported titers (Dueber et al. 
